SCHEMBL1736987

SCHEMBL1736987

Cc1ccc(C)c(N2CCN(C(=O)[C@@H]3CN(S(=O)(=O)c4ccccc4)C(=O)N3C(=O)OCc3ccccc3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.47
LMNA P02545 5/20 0.47
HTT P42858 3/20 0.45
OPRK1 P41145 1/20 0.45
TP53 P04637 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TSHR P16473 4/20 0.41
GAA P10253 2/20 0.41
ALOX12 P18054 1/20 0.41
USP2 O75604 3/20 0.41
MMP1 P03956 1/20 0.41
MMP3 P08254 1/20 0.41
MMP7 P09237 1/20 0.41
MMP9 P14780 1/20 0.41
MMP13 P45452 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1736989 1.00 MAPT (0.47) MAPTLMNAHTTOPRK1TP53
SCHEMBL1736751 0.91 MAPT (0.45) MAPTLMNAHTTOPRK1TP53
SCHEMBL1736756 0.91 MAPT (0.45) MAPTLMNAHTTOPRK1TP53
SCHEMBL1737320 0.89 ELANE (0.42) MAPTLMNAHTTOPRK1TP53
SCHEMBL1737317 0.89 ELANE (0.42) MAPTLMNAHTTOPRK1TP53
SCHEMBL1735731 0.86 LMNA (0.50) MAPTLMNAHTTOPRK1TP53
SCHEMBL1735732 0.86 LMNA (0.50) MAPTLMNAHTTOPRK1TP53
SCHEMBL1734743 0.86 MAPT (0.44) MAPTLMNAHTTOPRK1TP53
SCHEMBL1734739 0.86 MAPT (0.44) MAPTLMNAHTTOPRK1TP53
SCHEMBL1734866 0.83 MAPT (0.51) MAPTLMNAHTTOPRK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 EP disclosed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 WO disclosed
EP-2142533-A1 IMIDAZOLIDINONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-01-13 EP disclosed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 US disclosed
WO-2008119657-A1 IMIDAZOLIDINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 WO disclosed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES NR1H2, NR1H3, NR1I2 MAPT 4023/4885LMNA 1252/4885HTT 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.